Kymera Therapeutics Inc. share price logo

Kymera Therapeutics Inc.

NASDAQ: KYMR

Mid Cap

$110.55

+0.17

(+0.15%)

as on

Kymera Therapeutics Inc. Stock Performance

as on July 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $108.31
    $111.99
    downward going graph

    2.03%

    Downside

    1.30%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $36.65
    $130.05
    downward going graph

    66.85%

    Downside

    17.64%

    Upside

    downward going graph

Kymera Therapeutics Inc. share price movements today

Previous Close
$110.38
Open
$111.26
Volume
371.2K
Day's Low - High
$108.31 - $111.99
52 Week Low - High
$36.65 - $130.05

Kymera Therapeutics Inc. Historical Returns

1 Month Return
-5.22 %
3 Month Return
+ 30 %
1 Year Return
+ 141.06 %
3 Year Return
+ 404.94 %
5 Year Return
+ 89.82 %

Kymera Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Kymera Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$9.1B

EPS (TTM)

-3.5141

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-348.6M

Revenue (TTM)

51.5M

Profit Margin

0.00%

Return On Equity TTM

-27.09%

Kymera Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kymera Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Kymera Therapeutics Inc. image
Kymera Therapeutics Inc.
BUY$9.1B89.82%NA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$38.9B552.21%NA0.00%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$119.9B135.96%28.5735.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$68.3B11.18%16.4729.65%0.53%

Stock Returns calculator for Kymera Therapeutics Inc. Stock including INR - Dollar returns

The Kymera Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Kymera Therapeutics Inc. investment value today

Current value as on today

₹2,69,859

Returns

₹1,69,859

(+169.86%)

Returns from Kymera Therapeutics Inc. Stock

₹1,41,428 (+141.43%)

Dollar Impact

₹28,430 (+28.43%)

Analyst Recommendation on Kymera Therapeutics Inc. Stock

Based on 23 analysts

BUY

69.57%

Buy

30.43%

Hold

0.00%

Sell

Based on 23 analysts, 69.57% of analysts recommend a 'BUY' rating for Kymera Therapeutics Inc.. Average target price of $127.05

Kymera Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Kymera Therapeutics Inc..

What analysts predicted

12.99%UPSIDE

Target Price

$127.05

Current Price

$110.55

Analyzed by

23 Analysts

Target

$127.05

Kymera Therapeutics Inc. target price $127.05, a slight upside of 12.99% compared to current price of $110.55. According to 23 analysts rating.

Indian Investors' Interest in Kymera Therapeutics Inc. Stock

Search interest for Kymera Therapeutics Inc. Stock has increased by 1500% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:1500% versus previous 30 day period

Kymera Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
47
10
25
3
7
22
11
2
2
34
Gross Profit
47
10
25
3
7
22
9
-71
79
34
Operating Income
-19
-57
-50
-72
-80
-74
-84
-92
-97
-84
EBITDA
-13
-47
-40
-60
-68
-63
-74
-79
-85
-67
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
1
1
1
1
2
2
2
2
2
Income Before Tax
-14
-48
-42
-62
-70
-65
-76
-82
-87
-69
Income Tax Expense
4
0
-
-2
-
-
-
-
-
-
Net Income
-14
-48
-42
-62
-70
-65
-76
-82
-87
-69
Net Profit Margin
-30.01%
-472.02%
-163.98%
-1670.33%
-956.88%
-296.75%
-667.60%
-2973.05%
-3043.01%
-201.47%

Kymera Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
2
34
72
46
78
47
39
Gross Profit
0
2
34
72
46
78
47
39
Operating Income
-21
-42
-46
-100
-161
-165
-261
-349
EBITDA
-21
-40
-43
-97
-151
-143
-216
-303
Interest Expense
0
0
0
0
0
0
0
0
Depreciation
0
0
1
2
2
3
7
8
Income Before Tax
-21
-41
-45
-100
-154
-146
-223
-311
Income Tax Expense
0
0
-1
-2
-2
18
-
-
Net Income
-21
-41
-45
-100
-154
-146
-223
-311
Net Profit Margin
0.00%
-1407.36%
-133.96%
-137.60%
-330.60%
-186.99%
-475.57%
-794.39%

Kymera Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-48
-42
-62
-70
-65
-76
-82
-86
-69
Operating Cash Flow
-39
-42
-50
-61
-79
-59
-27
-66
-88
Investing Cash Flow
-330
15
-157
68
48
60
-235
-394
-142
Financing Cash Flow
353
1
250
2
0
245
39
705
18
Change in Cash
-16
-25
43
9
-30
245
-222
244
-212

Kymera Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-41
-45
-100
-154
-146
-223
-311
Operating Cash Flow
17
88
-128
-153
-102
-194
-232
Investing Cash Flow
-16
-422
-99
20
139
-404
-521
Financing Cash Flow
34
289
250
152
4
608
990
Change in Cash
36
-45
21
20
41
10
236

Global Institutional Holdings in Kymera Therapeutics Inc.

Funds
Holdings
Baker Bros Advisors LP
10.52%
venBio Select Advisor LLC
9.09%
BlackRock Inc
6.15%
Jennison Associates LLC
1.15%
Federated Hermes Inc
0.93%
See all

Kymera Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 25 June

    Thu, 10:49 PM

    -

    Kymera completes BROADEN2 trial enrollment ahead of schedule, boosting stock by 15.81% to a new 52-week high.

Insights on Kymera Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 2.76M → 34.36M (in $), with an average increase of 47.5% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, KYMR stock has moved up by 30.0%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -87.02M → -69.23M (in $), with an average increase of 25.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 407.1% return, outperforming this stock by 266.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 627.6% return, outperforming this stock by 223.6%

About Kymera Therapeutics Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
OrganisationKymera Therapeutics Inc.
Headquarters500 North Beacon Street, Watertown, MA, United States, 02472
IndustryBiotechnology
CEODr. Nello Mainolfi M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Kymera Therapeutics Inc.

Name

Title

Dr. Nello Mainolfi M.D., Ph.D.

Co-Founder, President, CEO & Director

Dr. Jared A. Gollob M.D.

Chief Medical Officer

Ms. Justine E. Koenigsberg

Vice President of Investor Relations

Dr. Neil Graham M.D., M.P.H., MBBS

Chief Development Officer

Mr. Brian Albarran M.B.A., Ph.D.

SVP of Corporate Strategy

Dr. Juliet Williams B.A Ph.D.

Head of Research

Mr. Bruce N. Jacobs CFA

Chief Financial Officer

Mr. Brian R. Adams J.D.

Chief Legal Officer & Corporate Secretary

Mr. Noah Goodman M.B.A.

Chief Business Officer

Dr. Jeremy G. Chadwick Ph.D.

Advisor

FAQs

What is Kymera Therapeutics Inc. share price today?

Kymera Therapeutics Inc. share price today is $110.55 as on at the close of the market. Kymera Therapeutics Inc. share today touched a day high of $111.99 and a low of $108.31.

What is the 52 week high and 52 week low for Kymera Therapeutics Inc. share?

Kymera Therapeutics Inc. share touched a 52 week high of $130.05 on and a 52 week low of $36.65 on . Kymera Therapeutics Inc. stock price today i.e. is closed at $110.55,which is 14.99% down from its 52 week high and 201.64% up from its 52 week low.

What is Kymera Therapeutics Inc.'s market capitalisation today?

Kymera Therapeutics Inc. market capitalisation is $0.01T as on .

How to invest in Kymera Therapeutics Inc. Stock (KYMR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kymera Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kymera Therapeutics Inc. Shares that will get you 0.0136 shares as per Kymera Therapeutics Inc. share price of $110.55 per share as on July 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Kymera Therapeutics Inc. Stock (KYMR) from India?

Indian investors can start investing in Kymera Therapeutics Inc. (KYMR) shares with as little as ₹96.552 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹965.52 in Kymera Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Kymera Therapeutics Inc. share’s latest price of $110.55 as on July 25, 2026 at 1:29 am IST, you will get 0.0905 shares of Kymera Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Kymera Therapeutics Inc. has given to Indian investors in the last 5 years?

Kymera Therapeutics Inc. stock has given 89.82% share price returns and 29.46% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?